KIF1A

JANUARY 27, 2024

#ScienceSaturday posts share exciting scientific developments and educational resources with the KAND community. Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. Rare Roundup KRIBB develops new gene therapy candidate for hereditary spastic paraplegia This week we’re flipping the format and starting with our Rare Roundup, after families contacted us with this article about

Therapies 111

Therapies Small Molecule DNA Treatment 111

Drugs.com

JANUARY 27, 2024

SATURDAY, Jan. 27, 2024 9HealthDay News) -- When should you worry about a rash?Rashes may look alike, but while over-the-counter medications can treat some rashes, others can signal a more serious condition, the American Academy of Dermatology (AAD).

Doctors 96

Doctors 96

Covalent Modifiers

JANUARY 27, 2024

Yizhen Jin , Sadhan Jana , Mikail E. Abbasov , Hening Lin bioRxiv 2024.01.22.576576; doi: [link] The emerging antibiotic resistance requires the development of new antibiotics working on novel bacterial targets. Here, we reported an antibiotic discovery workflow by combining the cysteine-reactive compound library phenotypic screening with activity-based protein profiling, which enables the rapid identification of lead compounds as well as new druggable targets in pathogens.

Drugs 82

Drugs Research 82

Drug Patent Watch

JANUARY 27, 2024

Annual Drug Patent Expirations for ORGOVYX Orgovyx is a drug marketed by Sumitomo Pharma and is included in one NDA. It is available from one supplier. There are eight patents… The post New patent expiration for Sumitomo Pharma drug ORGOVYX appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 64

Drugs Marketing 64

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Treatment

KIF1A

JANUARY 27, 2024

Dear KAND Community, As we step into a new year, I want to extend heartfelt wishes to each and every one of you. May this year bring hope, strength, and breakthroughs on our collective journey. In the face of challenges, your resilience shines brightly, inspiring us all. Let the new year be filled with moments of joy, progress, and community support.

International 52

International Treatment Research Science 52

Drug Patent Watch

JANUARY 27, 2024

This chart shows the drugs with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the long… The post Which drugs have the most supplementary protection certificates? appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59

Drugs Pharmaceuticals 59

Drug Patent Watch

JANUARY 27, 2024

Annual Drug Patent Expirations for LINZESS Linzess is a drug marketed by Abbvie and is included in one NDA. It is available from one supplier. There are twelve patents protecting… The post New patent expiration for Abbvie drug LINZESS appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59

Drugs Marketing 59

Drug Patent Watch

JANUARY 27, 2024

Annual Drug Patent Expirations for RIVIVE Rivive is a drug marketed by Harm Reduction Therp and is included in one NDA. It is available from one supplier. There is one… The post New patent for Harm Reduction drug RIVIVE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59

Drugs Marketing 59